EUVIMEDEUVIMED entdecken
Open Access

Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV

Cecile D Lahiri, C Christina Mehta, Craig Sykes, Sheri D Weiser, Frank Palella, Jordan E Lake, John W Mellors, Deborah Gustafson, Audrey L French, Adaora A Adimora, Deborah Konkle-Parker, Anjali Sharma und 7 weitere

AIDS Research and Human Retroviruses · 2023

DOI: 10.1089/aid.2022.0185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AIDS Research and Human Retroviruses, 2023. Verfasst von Cecile D Lahiri und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV Integrase Inhibitors, HIV-1, HIV Integrase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIA NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Integrase strand-transfer inhibitors (INSTIs) are associated with weight gain in women living with HIV (WLH). Relationships between drug exposure, baseline obesity, and INSTI-associated weight gain remain unclear. Data from 2006 to 2016 were analyzed from virally suppressed WLH enrolled in the Women's Interagency HIV Study, who switched/added an INSTI to antiretroviral therapy: [raltegravir (RAL), dolutegravir (DTG), or elvitegravir (EVG)]. Percent body weight change was calculated from weights obtained a median 6 months pre-INSTI and 14 months post-INSTI initiation. Hair concentrations were measured with validated liquid chromatography-mass spectrometry (MS)/MS assays. Baseline (preswitch) weight status evaluated obese (body mass index, BMI, ≥30 kg/m 2 ) versus nonobese (BMI 500 cells/mm 3 , >75% with undetectable HIV-1 RNA. Over ∼1 year, women experienced median increases in body weight: 1.71% (−1.78, 5.00) with RAL; 2.40% (−2.82, 6.50) with EVG; and 2.48% (−3.60, 7.88) with DTG. Baseline obesity status modified the relationship between hair concentrations and percent weight change for DTG and RAL ( p' s < 0.05): higher DTG, yet lower RAL concentrations were associated with greater weight gain among nonobese women. Additional pharmacologic assessments are needed to understand the role of drug exposure in INSTI-associated weight gain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV Integrase InhibitorsHIV-1HIV IntegraseHumansFemaleMiddle AgedRaltegravir PotassiumHeterocyclic Compounds, 3-RingOxazinesWeight GainObesityDolutegravir

Stichwörter der Autor:innen

HIVintegrase inhibitorspharmacologyweight gainwomen

Substanzen

Raltegravir PotassiumHIV Integrase InhibitorsHeterocyclic Compounds, 3-RingOxazinesHIV IntegraseDolutegravir

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Clinical Pharmacology and Analytical Chemistry Core, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco School of Medicine, San Francisco, California, USA.
  • Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Chicago, Illinois, USA.
  • Division of Infectious Diseases, Department of Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Förderung

  • NHLBI NIH HHS
  • NIA NIH HHS
  • NIDDK NIH HHS
  • NIAMS NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Lahiri, C. D., Mehta, C. C., Sykes, C., Weiser, S. D., Palella, F., Lake, J. E., Mellors, J. W., Gustafson, D., French, A. L., Adimora, A. A., Konkle-Parker, D., Sharma, A., Bolivar, H., Kassaye, S. G., Rubin, L. H., Alvarez, J. A., Golub, E. T., Ofotokun, I., & Sheth, A. N. (2023). Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV. AIDS Research and Human Retroviruses. https://doi.org/10.1089/aid.2022.0185

Vancouver

Lahiri CD, Mehta CC, Sykes C, Weiser SD, Palella F, Lake JE, et al. Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV. AIDS Research and Human Retroviruses. 2023. doi:10.1089/aid.2022.0185

BibTeX
@article{Lahiri2023,
  author = {Lahiri, Cecile D and Mehta, C Christina and Sykes, Craig and Weiser, Sheri D and Palella, Frank and Lake, Jordan E and Mellors, John W and Gustafson, Deborah and French, Audrey L and Adimora, Adaora A and Konkle-Parker, Deborah and Sharma, Anjali and Bolivar, Hector and Kassaye, Seble G and Rubin, Leah H and Alvarez, Jessica A and Golub, Elizabeth T and Ofotokun, Igho and Sheth, Anandi N},
  title = {Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV},
  journal = {AIDS Research and Human Retroviruses},
  year = {2023},
  doi = {10.1089/aid.2022.0185}
}
Kostenlos starten →